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hierarchical clustering, 16 samples were classiﬁed as sensitive and 31 
as resistant to Pemetrexed. 
Conclusions: The speciﬁcity of our microarray screen is 76% and 84% 
respectively, for sensitive and resistant samples, indicating that is a 
valid model to correctly classify the response to Pemetrexed in NSCLC 
surgical samples based upon gene proﬁle analysis. This strategy would 
be adequate for predicting outcome of treatment of NSCLC patients 
with Pemetrexed
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Background: Inherited polymorphisms of genes involved in the me-
tabolism and transport of irinotecan can affect irinotecan-pharmacoki-
netics (PK) and subsequent pharmacologic effects and toxicity. We ex-
amined 15 polymorphisms within seven genes with putative inﬂuence 
on metabolism and transport of irinotecan to deﬁne a pharmacogenetic 
model for predicting irinotecan PK and pharmacodynamics in patients 
with advanced non-small cell lung cancer (NSCLC). 
Methods: Blood samples from patients with advanced NSCLC 
enrolled in a phase II study of irinotecan and cisplatin chemotherapy 
were used for genotyping UGT1A1 211G>A (*6), UGT1A1*28, 
UGT1A7*3, UGT1A9 -118(T)9>10 (*22), ABCB1 1236C>T, 
2677G>T/A, 3435C>T, ABCC2 -24C>T, 1249G>A, 3972C>T, ABCG2 
34G>A, 421C>A, and SLCO1B1 -11187G>A, 388A>G, and 521T>C 
polymorphisms. Genotypes were correlated with irinotecan-PK and 
clinical outcome and multivariate logistic or Cox regression analysis 
was performed to identify independent predictors for PK, toxicity, 
tumor response, and survival.
Results: A total of 81 patients were enrolled and 77 were evaluable for 
tumor response. The overall response rate was 47% (36/77), the median 
progression-free survival (PFS) was 5.1 months, and the median overall 
survival (OS) was 14.3 months. The most common severe toxicity was 
NCI-CTC grade 4 neutropenia, which occurred in 22 (27%) patients. 
Pretreatment total bilirubin level (p=0.028) and OATP1B1 521T>C 
variant (p=0.020) were independently predictive for SN-38 AUC. 
Grade 4 neutropenia was signiﬁcantly associated with the UGT1A9*22 
(p=0.036) and OATPC1B1 521C>T (p=0.002) variants. The ABCC2 
3972C>T variant was predictive for tumor response (p=0.016). Predic-
tive factors for PFS were the UGT1A7*3 (p=0.005), UGT1A9*22 
(p=0.004), ABCC2-24C>T (p=0.004), and squamous cell histology 
(p=0.002), whereas, the OATP1B1 388A>G (p=0.006) and ECOG PS 
(p=0.005) were predictive for OS.
Conclusions: Patient selection based on pharmacogenetic model would 
be helpful for minimizing severe toxicity and maximizing the clinical 
beneﬁt of irinotecan-based chemotherapy for advanced NSCLC.
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Background: SUV39H2 is a histone methyltransferase enzyme that is 
required to methylate histone H3 lysine 9 (H3-K9) leading to transcrip-
tional repression or silencing of target genes. Recently, we observed 
a novel SNP in the 3’-UTR of SUV39H2 (1624 G>C) was associated 
with a statistically signiﬁcant increase in lung cancer risk (Carcinogen-
esis 27;2217-2222, 2006). We wanted to examine its clinical impli-
cation in a separate group of chemo-naive lung cancer patients who 
were prospectively enrolled in frontline chemotherapy trial protocols 
conducted at the National Cancer Center Hospital Korea. 
Methods: A total of 361 patients (195 NSCLC, 166 SCLC) were in-
cluded in this study. Of the 195 stage IIIb/IV NSCLC patients, 81 were 
given irinotecan/cisplatin upfront on NCC-041 (Cancer 106:873-80, 
2006) and 115 were given as front-line therapy either irinotecan/cis-
platin or gemcitabine/vinorelbine on NCC-079 protocol (Proc ASCO 
2006, #7134). Extensive disease (ED)-SCLC patients (n=99) were 
treated with irinotecan/cisplatin on NCC-055 protocol and limited dis-
ease (LD)-SCLC patients (n=67) were treated with irinotecan/cisplatin 
induction followed by concurrent chemoradiation therapy with etopo-
side/cisplatin on NCC-056 protocol (Proc ASCO 2007). The 1624G->C 
genotypes was determined by the TaqMan assay and direct sequencing, 
as previously reported, using DNA samples obtained from peripheral 
bloods of patients who were enrolled in the above clinical trials. 
Results: Of the 361 lung cancer patients, 60 (16.6%) had variant 
1624G>C genotypes (G/C or CC) while 301 (83.4%) had wild geno-
type. Ever smokers had higher frequency of variant 1624G>C geno-
types than never smokers (7/75 [9.3%] vs. 53/286 [18.5%], p=0.057). 
Adenocarcinoma tended to have less variant 1624G>C genotype than 
SCLC or other NSCLC than adenocarcinoma (12.9%, 18.7%, 20.0%, 
respectively), but the difference was not statistically signiﬁcant. After 
median follow-up of 30.8 months, 216 of 301 patients with wild type 
and 34 of 60 patients with variant 1624G>C genotypes died. Overall, 
patients with variant 1624G>C genotypes survived signiﬁcantly longer 
than those with wild genotype (median survival, 25.3 vs.15.8 months; 
2-year survival rate, 50.4% vs. 30.6%, p=0.014). Multivariate analysis 
using the Cox proportional hazard model showed variant 1624G>C 
genotype was a signiﬁcant prognostic factor for better survival with 
hazard ratio of 0.603 (95% CI, 0.417~0.871; p=0.007). Stage (LD/IIIb 
vs. ED/IV) and ECOG performance status (0-1 vs. 2), and age (<55 
vs. ≥55) were also a signiﬁcant prognostic factor with hazard ratio of 
1.927 (95% CI, 1.391-2.670; p<0.001), 1.638 (95% CI, 1.152-2.330; 
p=0.006), and 1.392 (95% CI, 1.039-1.863; p=0.026), respectively. In 
this analysis, however, smoking (never vs. ever), histology (SCLC vs. 
NSCLC), and gender (male vs. female) were not a signiﬁcant prognos-
tic factor. When the overall survival of patients with NSCLC and those 
with SCLC was analyzed separately, the results were similar. 
Conclusions: These results provide the ﬁrst evidence that a novel 
SUV39H2 polymorphism (1624G>C) is not only an important predic-
tive marker for lung cancer susceptibility for the smokers but also an 
important prognostic factor for lung cancer patients after frontline 
chemotherapy. 
